Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 50 of 116 for:    Atenolol

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03070730
Recruitment Status : Terminated (Recruitment was slow and subjects declined participation after signing the ICF.)
First Posted : March 6, 2017
Results First Posted : May 18, 2017
Last Update Posted : May 18, 2017
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Roy Freeman, MD, Beth Israel Deaconess Medical Center

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Triple (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions Postural Orthostatic Tachycardia Syndrome
Orthostatic Intolerance
Interventions Drug: Droxidopa
Drug: Atenolol
Drug: Placebos
Enrollment 8
Recruitment Details  
Pre-assignment Details Participants that were enrolled in the study were excluded from the study because they either did not meet eligibility criteria or decided not to participate.
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Period Title: Overall Study
Started 0 0 0
Completed 0 0 0
Not Completed 0 0 0
Arm/Group Title Atenolol Placebos Droxidopa Total
Hide Arm/Group Description

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Total of all reporting groups
Overall Number of Baseline Participants 0 0 0 0
Hide Baseline Analysis Population Description
Participants that were enrolled in the study were not randomized. They did not meet eligibility criteria, or decided not to participate.
Age, Customized  
Number Analyzed 0 participants 0 participants 0 participants 0 participants
0 0 0
Sex: Female, Male  
Number Analyzed 0 participants 0 participants 0 participants 0 participants
Female 0 0 0
Male 0 0 0
Race (NIH/OMB)  
Number Analyzed 0 participants 0 participants 0 participants 0 participants
American Indian or Alaska Native 0 0 0 0
Asian 0 0 0 0
Native Hawaiian or Other Pacific Islander 0 0 0 0
Black or African American 0 0 0 0
White 0 0 0 0
More than one race 0 0 0 0
Unknown or Not Reported 0 0 0 0
1.Primary Outcome
Title Change in Maximal Postural Tachycardia During Tilt
Hide Description Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.
Time Frame Up to 3 days after randomization
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
2.Primary Outcome
Title Change Maximal Postural Tachycardia During Tilt
Hide Description Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.
Time Frame 2 weeks after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
3.Primary Outcome
Title Change Maximal Postural Tachycardia During Tilt
Hide Description Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.
Time Frame 2 weeks after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
4.Primary Outcome
Title Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
Hide Description A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.
Time Frame up to 3 days after randomization
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
5.Primary Outcome
Title Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
Hide Description A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.
Time Frame 2 weeks after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
6.Primary Outcome
Title Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
Hide Description A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.
Time Frame 2 weeks after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
7.Secondary Outcome
Title Change in Blood Pressure From Baseline
Hide Description [Not Specified]
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
8.Secondary Outcome
Title Change in Blood Pressure From Baseline
Hide Description [Not Specified]
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
9.Secondary Outcome
Title Change in Blood Pressure From Baseline
Hide Description [Not Specified]
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
10.Secondary Outcome
Title Change in Heart Rate From Baseline
Hide Description [Not Specified]
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
11.Secondary Outcome
Title Change in Heart Rate From Baseline
Hide Description [Not Specified]
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
12.Secondary Outcome
Title Change in Heart Rate From Baseline
Hide Description [Not Specified]
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
13.Secondary Outcome
Title Change in Vascular Resistance From Baseline
Hide Description [Not Specified]
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
14.Secondary Outcome
Title Change in Vascular Resistance From Baseline
Hide Description [Not Specified]
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
15.Secondary Outcome
Title Change in Vascular Resistance From Baseline
Hide Description [Not Specified]
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
16.Secondary Outcome
Title Change in Muscle Sympathetic Nerve Activity From Baseline
Hide Description [Not Specified]
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
17.Secondary Outcome
Title Change in Muscle Sympathetic Nerve Activity From Baseline
Hide Description [Not Specified]
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
18.Secondary Outcome
Title Change in Muscle Sympathetic Nerve Activity From Baseline
Hide Description [Not Specified]
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
19.Secondary Outcome
Title Change in Physical Functioning-SF-36 Q From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
20.Secondary Outcome
Title Change in Physical Functioning-SF-36 Q From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
21.Secondary Outcome
Title Change in Physical Functioning-SF-36 Q From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
22.Secondary Outcome
Title Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse".
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
23.Secondary Outcome
Title Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse".
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
24.Secondary Outcome
Title Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse".
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
25.Secondary Outcome
Title Change in Physical Functioning- HADS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
26.Secondary Outcome
Title Change in Physical Functioning- HADS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
27.Secondary Outcome
Title Change in Physical Functioning- HADS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
28.Secondary Outcome
Title Change in Physical Functioning-CIS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
29.Secondary Outcome
Title Change in Physical Functioning-CIS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
30.Secondary Outcome
Title Change in Physical Functioning-CIS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
31.Secondary Outcome
Title Change in Physical Functioning-MFI From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
32.Secondary Outcome
Title Change in Physical Functioning-MFI From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
33.Secondary Outcome
Title Change in Physical Functioning-MFI From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
34.Secondary Outcome
Title Change in Physical Functioning-FSS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
35.Secondary Outcome
Title Change in Physical Functioning-FSS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
36.Secondary Outcome
Title Change in Physical Functioning-FSS From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
37.Secondary Outcome
Title Change in Physical Functioning-EuroQOL From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
38.Secondary Outcome
Title Change in Physical Functioning-EuroQOL From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
39.Secondary Outcome
Title Change in Physical Functioning-EuroQOL From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
40.Secondary Outcome
Title Change in Physical Functioning-OI From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.
Time Frame 1 week after first intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
41.Secondary Outcome
Title Change in Physical Functioning-OI From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.
Time Frame 1 week after second intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
42.Secondary Outcome
Title Change in Physical Functioning-OI From Baseline
Hide Description Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.
Time Frame 1 week after third intervention
Hide Outcome Measure Data
Hide Analysis Population Description
[Not Specified]
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description:

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

Overall Number of Participants Analyzed 0 0 0
No data displayed because Outcome Measure has zero total analyzed.
Time Frame [Not Specified]
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title Atenolol Placebos Droxidopa
Hide Arm/Group Description

In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to placebo tid.

Placebo is used to control the administration effect.

Placebos: Placebo: t.i.d

In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.

Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.

Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.

Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d

Atenolol: Atenolol: 50 mg Q.D.

Placebos: Placebo: t.i.d

All-Cause Mortality
Atenolol Placebos Droxidopa
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   0/0   0/0   0/0 
Show Serious Adverse Events Hide Serious Adverse Events
Atenolol Placebos Droxidopa
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   0/0   0/0   0/0 
Show Other (Not Including Serious) Adverse Events Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 0%
Atenolol Placebos Droxidopa
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   0/0   0/0   0/0 
The trial was terminated early due to difficulties in the recruitment process. Subjects were found to be ineligible, or decided not to participate in the study.
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Dr. Roy Freeman
Organization: Beth Israel Deaconess Medical Center
Phone: 617-632-8454
EMail: rfreeman@bidmc.harvard.edu
Publications:
Layout table for additonal information
Responsible Party: Roy Freeman, MD, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier: NCT03070730     History of Changes
Other Study ID Numbers: 2011P000246
R01HL059459 ( U.S. NIH Grant/Contract )
First Submitted: February 27, 2012
First Posted: March 6, 2017
Results First Submitted: April 12, 2017
Results First Posted: May 18, 2017
Last Update Posted: May 18, 2017